Published in Am J Gastroenterol on July 19, 2011
A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care. Hepatology (2013) 1.46
The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. J Viral Hepat (2013) 1.37
Barriers to hepatitis C treatment. Liver Int (2012) 1.13
Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care. World J Gastroenterol (2013) 0.93
Assessment of motivating factors associated with the initiation and completion of treatment for chronic hepatitis C virus (HCV) infection. BMC Infect Dis (2013) 0.93
Patients receiving opioid maintenance treatment in primary care: successful chronic hepatitis C care in a real world setting. BMC Infect Dis (2013) 0.88
Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic Hepatitis C care continuum. Int J Drug Policy (2015) 0.88
Time to rethink antiviral treatment for hepatitis C in patients with coexisting mental health/substance abuse issues. Dig Dis Sci (2012) 0.87
Chronic hepatitis C and antiviral treatment regimens: where can psychology contribute? J Consult Clin Psychol (2012) 0.87
All-cause mortality and liver-related outcomes following successful antiviral treatment for chronic hepatitis C. Dig Dis Sci (2014) 0.86
Alcohol use disorder and its impact on chronic hepatitis C virus and human immunodeficiency virus infections. World J Hepatol (2016) 0.85
Eligibility of persons who inject drugs for treatment of hepatitis C virus infection. World J Gastroenterol (2014) 0.82
Physical, social, and psychological consequences of treatment for hepatitis C : a community-based evaluation of patient-reported outcomes. Patient (2013) 0.79
An international perspective on using opioid substitution treatment to improve hepatitis C prevention and care for people who inject drugs: Structural barriers and public health potential. Int J Drug Policy (2015) 0.77
What defines high quality care for patients with chronic hepatitis C and why should we care? Dig Dis Sci (2014) 0.75
What psychiatric screening and monitoring might be needed with the new generation of hepatitis C treatments? World J Virol (2015) 0.75
Hepatitis C, mental health and equity of access to antiviral therapy: a systematic narrative review. Int J Equity Health (2013) 0.75
Medical and Behavioral Approaches to Engage People Who Inject Drugs Into Care for Hepatitis C Virus Infection. Addict Disord Their Treat (2017) 0.75
Direct-acting antiviral agents for HCV infection affecting people who inject drugs. Nat Rev Gastroenterol Hepatol (2017) 0.75
Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption--II. Addiction (1993) 41.55
The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med (1999) 16.35
Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med (2002) 3.49
Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness. Am J Public Health (2001) 3.46
Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology (2009) 3.10
Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection. Am J Gastroenterol (2005) 3.09
Do Internet-based support interventions change perceptions of social support?: An experimental trial of approaches for supporting diabetes self-management. Am J Community Psychol (2002) 3.06
Brief strengths-based case management promotes entry into HIV medical care: results of the antiretroviral treatment access study-II. J Acquir Immune Defic Syndr (2008) 2.36
A systematic review of psychosocial research on psychosocial interventions for people with co-occurring severe mental and substance use disorders. J Subst Abuse Treat (2007) 2.24
National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002. Hepatology (2002) 2.19
Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? N Engl J Med (2001) 2.12
Barriers to the treatment of hepatitis C. Patient, provider, and system factors. J Gen Intern Med (2005) 1.97
Hepatitis C, interferon alfa, and depression. Hepatology (2000) 1.91
Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology (2003) 1.86
Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. Clin Infect Dis (2005) 1.80
Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. Hepatology (2007) 1.79
Co-occurring Hepatitis C, substance use, and psychiatric illness: treatment issues and developing integrated models of care. J Urban Health (2004) 1.54
Prevalence of human immunodeficiency virus, hepatitis B, and hepatitis C among homeless persons with co-occurring severe mental illness and substance use disorders. Compr Psychiatry (2003) 1.47
Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: challenges and opportunities. Clin Infect Dis (2005) 1.41
Hepatitis C in methadone maintenance patients: prevalence and public policy implications. J Addict Dis (2001) 1.33
Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules? Addiction (2004) 1.27
Management of patients with hepatitis C in a community population: diagnosis, discussions, and decisions to treat. Ann Fam Med (2004) 1.24
Integrated psychiatric/medical care in a chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes. Am J Gastroenterol (2006) 1.23
Psychiatric and substance use disorders in individuals with hepatitis C: epidemiology and management. Drugs (2006) 1.20
A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infection. J Clin Gastroenterol (2002) 1.17
Addressing tri-morbidity (hepatitis C, psychiatric disorders, and substance use): the importance of routine mental health screening as a component of a comanagement model of care. Clin Infect Dis (2005) 1.14
Integrating care for patients with infectious, psychiatric, and substance use disorders: concepts and approaches. AIDS (2005) 1.12
Integrating multiple programme and policy approaches to hepatitis C prevention and care for injection drug users: a comprehensive approach. Int J Drug Policy (2007) 1.11
A model of integrated primary care for HIV-positive patients with underlying substance use and mental illness. AIDS Care (2007) 1.10
Management of chronic hepatitis C in veterans: the potential of integrated care models. Am J Gastroenterol (2008) 1.08
Challenges in the treatment of patients coinfected with HIV and hepatitis C virus: need for team care. Clin Infect Dis (2005) 1.07
Hepatitis C treatment eligibility and outcomes among patients with psychiatric illness. Psychiatr Serv (2006) 1.07
Spectrum of disease in U.S. veteran patients with hepatitis C. Am J Gastroenterol (2002) 1.05
Antiviral therapy for hepatitis C: why are so few patients being treated? J Antimicrob Chemother (2010) 1.05
Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support. Eur J Gastroenterol Hepatol (2010) 1.04
Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection. Int J Drug Policy (2007) 1.03
High deferral rates and poorer treatment outcomes for HCV patients with psychiatric and substance use comorbidities. Dig Dis Sci (2007) 1.03
Literature on integrated HIV care: a review. AIDS Care (2004) 0.98
Barriers to accessing care in patients with chronic hepatitis C: the impact of depression. Aliment Pharmacol Ther (2010) 0.95
Barriers to hepatitis C virus treatment in a Canadian HIV-hepatitis C virus coinfection tertiary care clinic. Can J Gastroenterol (2008) 0.93
A multidisciplinary therapeutic approach for reducing the risk of psychiatric side effects in patients with chronic hepatitis C treated with pegylated interferon α and ribavirin. J Clin Gastroenterol (2010) 0.90
Impact on adherence and sustained virological response of psychiatric side effects during peginterferon and ribavirin therapy for chronic hepatitis C. Aliment Pharmacol Ther (2006) 0.89
Making it happen: managed care considerations in vanquishing hepatitis C. Am J Manag Care (2007) 0.87
Case management community care for people living with HIV/AIDS (PLHAs). AIDS Care (2007) 0.84
Supported medical care: a multi-faceted approach to helping HIV/hepatitis C virus co-infected adults with serious mental illness. AIDS (2005) 0.80
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med (2014) 7.73
Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med (2005) 7.18
Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med (2011) 6.31
Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology (2006) 4.90
Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology (2007) 3.87
Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol (2005) 3.10
Influence of individual- and area-level measures of socioeconomic status on obesity, unhealthy eating, and physical inactivity in Canadian adolescents. Am J Clin Nutr (2006) 2.45
Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatology (2010) 2.28
Circulating levels of inflammatory cytokines and risk of colorectal adenomas. Cancer Res (2008) 2.13
Side effects of therapy for chronic hepatitis C. Gastroenterology (2003) 2.04
Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl (2004) 1.96
Association between hemochromatosis (HFE) gene mutation carrier status and the risk of colon cancer. J Natl Cancer Inst (2003) 1.80
Patient and graft survival in hepatitis C recipients after adult living donor liver transplantation in the United States. Liver Transpl (2004) 1.74
Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology (2010) 1.74
Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterology (2003) 1.70
Serum citrulline levels correlate with enteral tolerance and bowel length in infants with short bowel syndrome. J Pediatr (2005) 1.63
Increased rectal microbial richness is associated with the presence of colorectal adenomas in humans. ISME J (2012) 1.62
Implementation of an ED protocol for pain management at triage at a busy Level I trauma center. J Emerg Nurs (2004) 1.61
Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response. Hepatology (2011) 1.53
Insulin resistance, apoptosis, and colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev (2005) 1.52
Delayed neuropsychologic dysfunction after liver transplantation for acute liver failure: a matched, case-controlled study. Liver Transpl (2002) 1.52
Cross-national study of fighting and weapon carrying as determinants of adolescent injury. Pediatrics (2005) 1.50
Detection of dysplasia in Barrett's esophagus with in vivo depth-resolved nuclear morphology measurements. Gastroenterology (2010) 1.48
Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C. Gastroenterology (2006) 1.47
A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care. Hepatology (2013) 1.46
Severe villus atrophy and chronic malabsorption induced by azathioprine. Gastroenterology (2003) 1.46
Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). J Hepatol (2002) 1.43
Current therapy for hepatitis C: pegylated interferon and ribavirin. Clin Liver Dis (2003) 1.40
How qualitative methods contribute to understanding combination antiretroviral therapy adherence. J Acquir Immune Defic Syndr (2006) 1.39
The FDA, bridging data, and hepatitis C. Hepatology (2013) 1.38
Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C. J Clin Pharmacol (2009) 1.37
Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract. Drug Metab Dispos (2007) 1.31
Injuries experienced by infant children: a population-based epidemiological analysis. Pediatrics (2003) 1.30
Early hepatic stellate cell activation is associated with advanced fibrosis after liver transplantation in recipients with hepatitis C. Liver Transpl (2005) 1.27
Multiple risk behavior and injury: an international analysis of young people. Arch Pediatr Adolesc Med (2002) 1.25
Barriers to and facilitators of adherence to pediatric antiretroviral therapy in a sub-Saharan setting: insights from a qualitative study. AIDS Patient Care STDS (2011) 1.24
Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus. Gastroenterology (2012) 1.24
Impact of comorbidity on colorectal cancer screening in the veterans healthcare system. Clin Gastroenterol Hepatol (2007) 1.21
Modification of the natural history of adult-onset acid maltase deficiency by nutrition and exercise therapy. Muscle Nerve (2007) 1.20
Nonsteroidal anti-inflammatory drugs, apoptosis, and colorectal adenomas. Gastroenterology (2002) 1.20
Traumatic spinal cord injury in Ontario, Canada. J Trauma (2003) 1.20
Implementation and evaluation of a clinic-based behavioral intervention: positive steps for patients with HIV. AIDS Patient Care STDS (2008) 1.18
The pharmacokinetics of silymarin is altered in patients with hepatitis C virus and nonalcoholic Fatty liver disease and correlates with plasma caspase-3/7 activity. Drug Metab Dispos (2008) 1.17
Prospective analysis of depression during peginterferon and ribavirin therapy of chronic hepatitis C: results of the Virahep-C study. Am J Gastroenterol (2009) 1.16
Stages of development and injury patterns in the early years: a population-based analysis. BMC Public Health (2006) 1.14
Barriers to hepatitis C treatment. Liver Int (2012) 1.13
The risk of end stage liver disease and hepatocellular carcinoma among persons infected with hepatitis C virus: publication bias? Am J Gastroenterol (2003) 1.12
Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin. Am J Gastroenterol (2008) 1.11
Neurocognitive functioning and HAART in HIV and hepatitis C virus co-infection. AIDS (2006) 1.08
Dietary patterns, food groups, and rectal cancer risk in Whites and African-Americans. Cancer Epidemiol Biomarkers Prev (2009) 1.05
5,10-methylenetetrahydrofolate reductase 677 and 1298 polymorphisms, folate intake, and microsatellite instability in colon cancer. Cancer Epidemiol Biomarkers Prev (2005) 1.05
Social stigmatization and hepatitis C virus infection. J Clin Gastroenterol (2006) 1.05
Intake of polyunsaturated fatty acids and distal large bowel cancer risk in whites and African Americans. Am J Epidemiol (2010) 1.05
Assessing the validity of self-reported medication adherence in hepatitis C treatment. Ann Pharmacother (2007) 1.04
R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. Hepatology (2008) 1.03
Regional differences in deceased donor liver transplantation and their implications for organ utilization and allocation. Clin Transplant (2011) 1.03
High deferral rates and poorer treatment outcomes for HCV patients with psychiatric and substance use comorbidities. Dig Dis Sci (2007) 1.03
Race and colorectal cancer screening: a population-based study in North Carolina. N C Med J (2004) 1.02
Genetic variants in IGF-I, IGF-II, IGFBP-3, and adiponectin genes and colon cancer risk in African Americans and Whites. Cancer Causes Control (2012) 1.02
Surrogates' perceptions about feeding tube placement decisions. Patient Educ Couns (2006) 1.01
Association of plasma endotoxin, inflammatory cytokines and risk of colorectal adenomas. BMC Cancer (2013) 1.00
Pantoprazole reduces the size of postbanding ulcers after variceal band ligation: a randomized, controlled trial. Hepatology (2005) 1.00
Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study. J Hepatol (2005) 0.99
Choline intake and genetic polymorphisms influence choline metabolite concentrations in human breast milk and plasma. Am J Clin Nutr (2010) 0.99
Health locus of control predicts survival after lung transplant. J Health Psychol (2005) 0.97
Certificate of added qualification for hepatology: vindication not vanity. Gastroenterology (2005) 0.96
Improved prevention counseling by HIV care providers in a multisite, clinic-based intervention: Positive STEPs. AIDS Educ Prev (2009) 0.95
Physicians' decisions about continuing or stopping colon cancer screening in the elderly: a qualitative study. J Gen Intern Med (2009) 0.95
Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trial. Am J Gastroenterol (2004) 0.95
Psychological well-being of surgery residents before the 80-hour work week: a multiinstitutional study. J Am Coll Surg (2004) 0.94
Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential. Eur J Gastroenterol Hepatol (2014) 0.93
HIV-infected prison inmates: depression and implications for release back to communities. AIDS Behav (2008) 0.92
Differences in the disposition of silymarin between patients with nonalcoholic fatty liver disease and chronic hepatitis C. Drug Metab Dispos (2011) 0.92
Dietary choline requirements of women: effects of estrogen and genetic variation. Am J Clin Nutr (2010) 0.92
Does physical activity modify the association between body mass index and colorectal adenomas? Nutr Cancer (2005) 0.92
Venue-based recruitment of women at elevated risk for HIV: an HIV Prevention Trials Network study. J Womens Health (Larchmt) (2014) 0.91
Rationale, challenges, and participants in a Phase II trial of a botanical product for chronic hepatitis C. Clin Trials (2011) 0.89
Local IGFBP-3 mRNA expression, apoptosis and risk of colorectal adenomas. BMC Cancer (2008) 0.89
Insurance, employment, and psychosocial consequences of a diagnosis of hereditary hemochromatosis in subjects without end organ damage. Am J Gastroenterol (2003) 0.89
Detection of undiagnosed HIV among state prison entrants. JAMA (2013) 0.89
Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin. Scand J Gastroenterol (2007) 0.88
Shared decision making for prostate cancer screening: the results of a combined analysis of two practice-based randomized controlled trials. BMC Med Inform Decis Mak (2012) 0.87
Time to rethink antiviral treatment for hepatitis C in patients with coexisting mental health/substance abuse issues. Dig Dis Sci (2012) 0.87
Rates and external causes of blunt head trauma in Ontario: analysis and review of Ontario Trauma Registry datasets. Chronic Dis Can (2004) 0.87
Apoptosis in normal rectal mucosa, baseline adenoma characteristics, and risk of future adenomas. Cancer Epidemiol Biomarkers Prev (2008) 0.87
Chronic hepatitis C and antiviral treatment regimens: where can psychology contribute? J Consult Clin Psychol (2012) 0.87
Use of nonsteroidal antiinflammatory drugs and distal large bowel cancer in whites and African Americans. Am J Epidemiol (2008) 0.86
Unexpected maintenance of hepatitis C viral diversity following liver transplantation. J Virol (2012) 0.86
HPTN 062: a feasibility and acceptability pilot intervention to reduce HIV transmission risk behaviors among individuals with acute and early HIV infection in Lilongwe, Malawi. AIDS Behav (2014) 0.86
Polymorphisms in methionine synthase, methionine synthase reductase and serine hydroxymethyltransferase, folate and alcohol intake, and colon cancer risk. J Nutrigenet Nutrigenomics (2008) 0.86
Tangible resources for preparing patients for antiviral therapy for chronic hepatitis C. Dig Dis Sci (2012) 0.86
Deep sequencing analysis of HCV NS3 resistance-associated variants and mutation linkage in liver transplant recipients. PLoS One (2013) 0.85
Persistent portosystemic shunts after liver transplantation causing episodic hepatic encephalopathy. Dig Dis Sci (2009) 0.84
Associations of red meat, fat, and protein intake with distal colorectal cancer risk. Nutr Cancer (2010) 0.84
Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C. J Hepatol (2003) 0.83